331 related articles for article (PubMed ID: 17156374)
21. Differences in two mice strains on kainic acid-induced amygdalar seizures.
Kasugai M; Akaike K; Imamura S; Matsukubo H; Tojo H; Nakamura M; Tanaka S; Sano A
Biochem Biophys Res Commun; 2007 Jun; 357(4):1078-83. PubMed ID: 17467670
[TBL] [Abstract][Full Text] [Related]
22. A metallothionein mimetic peptide protects neurons against kainic acid-induced excitotoxicity.
Sonn K; Pankratova S; Korshunova I; Zharkovsky A; Bock E; Berezin V; Kiryushko D
J Neurosci Res; 2010 Apr; 88(5):1074-82. PubMed ID: 19937811
[TBL] [Abstract][Full Text] [Related]
23. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
24. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.
Ariano MA; Wagle N; Grissell AE
J Neurosci Res; 2005 Jun; 80(5):634-45. PubMed ID: 15880743
[TBL] [Abstract][Full Text] [Related]
25. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.
Beal MF; Kowall NW; Ellison DW; Mazurek MF; Swartz KJ; Martin JB
Nature; 1986 May 8-14; 321(6066):168-71. PubMed ID: 2422561
[TBL] [Abstract][Full Text] [Related]
26. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
Winkler C; Gil JM; Araújo IM; Riess O; Skripuletz T; von Hörsten S; Petersén A
Brain Res Bull; 2006 Apr; 69(3):306-10. PubMed ID: 16564426
[TBL] [Abstract][Full Text] [Related]
27. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
[TBL] [Abstract][Full Text] [Related]
28. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Sapko MT; Guidetti P; Yu P; Tagle DA; Pellicciari R; Schwarcz R
Exp Neurol; 2006 Jan; 197(1):31-40. PubMed ID: 16099455
[TBL] [Abstract][Full Text] [Related]
29. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.
Hickey MA; Morton AJ
J Neurochem; 2000 Nov; 75(5):2163-71. PubMed ID: 11032906
[TBL] [Abstract][Full Text] [Related]
30. Increase in bax expression and apoptosis are associated in Huntington's disease progression.
Teles AV; Rosenstock TR; Okuno CS; Lopes GS; Bertoncini CR; Smaili SS
Neurosci Lett; 2008 Jun; 438(1):59-63. PubMed ID: 18468793
[TBL] [Abstract][Full Text] [Related]
31. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
[TBL] [Abstract][Full Text] [Related]
32. Genetic background markedly influences vulnerability of the hippocampal neuronal organization in the "twitcher" mouse model of globoid cell leukodystrophy.
Tominaga K; Matsuda J; Kido M; Naito E; Yokota I; Toida K; Ishimura K; Suzuki K; Kuroda Y
J Neurosci Res; 2004 Aug; 77(4):507-16. PubMed ID: 15264220
[TBL] [Abstract][Full Text] [Related]
33. Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.
Jiang W; Büchele F; Papazoglou A; Döbrössy M; Nikkhah G
J Neurosci Methods; 2009 May; 179(2):219-23. PubMed ID: 19428530
[TBL] [Abstract][Full Text] [Related]
34. Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
De March Z; Zuccato C; Giampà C; Patassini S; Bari M; Gasperi V; De Ceballos ML; Bernardi G; Maccarrone M; Cattaneo E; Fusco FR
Neuroscience; 2008 Mar; 152(3):734-40. PubMed ID: 18313855
[TBL] [Abstract][Full Text] [Related]
35. Dearth of glutamate transporters contributes to striatal excitotoxicity.
Brustovetsky T; Purl K; Young A; Shimizu K; Dubinsky JM
Exp Neurol; 2004 Oct; 189(2):222-30. PubMed ID: 15380474
[TBL] [Abstract][Full Text] [Related]
36. Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history.
Diguet E; Fernagut PO; Normand E; Centelles L; Mulle C; Tison F
Neurobiol Dis; 2004 Apr; 15(3):667-75. PubMed ID: 15056475
[TBL] [Abstract][Full Text] [Related]
37. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
38. Differences in sensitivity to the convulsant pilocarpine in substrains and sublines of C57BL/6 mice.
Müller CJ; Gröticke I; Hoffmann K; Schughart K; Löscher W
Genes Brain Behav; 2009 Jul; 8(5):481-92. PubMed ID: 19493016
[TBL] [Abstract][Full Text] [Related]
39. Increased susceptibility of glutathione peroxidase-1 transgenic mice to kainic acid-related seizure activity and hippocampal neuronal cell death.
Boonplueang R; Akopian G; Stevenson FF; Kuhlenkamp JF; Lu SC; Walsh JP; Andersen JK
Exp Neurol; 2005 Mar; 192(1):203-14. PubMed ID: 15698635
[TBL] [Abstract][Full Text] [Related]
40. IL-18 deficiency aggravates kainic acid-induced hippocampal neurodegeneration in C57BL/6 mice due to an overcompensation by IL-12.
Zhang XM; Duan RS; Chen Z; Quezada HC; Mix E; Winblad B; Zhu J
Exp Neurol; 2007 May; 205(1):64-73. PubMed ID: 17316614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
